- Headquarters
- Shanghai
- Founded
- 2018
- Business Model
- B2B
- Website
- anjipharma.com
- Total Funding
- $70.0M
- Last Round
- $70.0M Series BSep 2021
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Anji Pharma (also styled Anji Pharmaceuticals) was a Cambridge, Massachusetts and Shanghai-based clinical-stage biotech that used human genetics and population data to identify biologically validated drug targets for high-prevalence metabolic and oncology diseases. Its pipeline included ANJ900, a delayed-release metformin for type 2 diabetes with kidney disease, in Phase 3, and ANJ908 (pradigastat) in Phase 2. As of August 2026 the company's domain is inactive and its ANJ900 trial was marked suspended in 2023 for strategic reasons, indicating the company is no longer operating.
Summary
Anji Pharma (安济药业) is a Biotech company based in Shanghai, China, founded in 2018. It has raised $70.0M in total across 1 round, most recently a $70.0M Series B round in Sep 2021. Investors include CR Capital.
Funding History
Sep 2021
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
Global contract research organization providing comprehensive drug development and laboratory ser...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/anji-pharma"><img src="https://indexed.vc/api/badge/company/anji-pharma" alt="Anji Pharma (安济药业) on Indexed.vc" width="260" height="76" /></a>